Skip to main content

Table 1 Distribution of patients with inactive and active Behçet’s disease, according to clinical manifestations and medication use

From: Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet’s disease

  iBD (n = 31) (%) aBD (n = 30) (%)
Current Previous Current Previous
Clinical manifestations     
 Oral ulcers 0 31 (100) 21 (70.0) 30 (100)
 Genital ulcers 0 28 (90.3) 5 (16.7) 24 (80.0)
 Anterior uveitis 0 14 (45.2) 11 (36.7) 8 (26.7)
 Posterior uveitis 0 10 (32.3) 7 (23.3) 11 (36.7)
 Other ocular manifestationsa 0 5 (16.1) 4 (13.3) 5 (16.7)
 Pseudofolliculitis 0 18 (58.1) 6 (20.0) 11 (36.7)
 Erythema nodosum 0 15 (48.4) 8 (26.7) 14 (46.7)
 CNS 0 7 (22.6) 5 (16.7) 5 (16.7)
 Gastrointestinal 0 2 (6.5) 0 1 (3.3)
 Cardiovascular 0 5 (16.1) 3 (10.0) 4 (13.3)
 Pathergy 5 (16.1) 2 (6.7)
 Othersb 0 13 (41.9) 5 (16.7) 9 (30.0)
Disease duration, years, median/minimum–maximum 9/1 – 30 6/0 – 19
Age at BD onset, years, mean (SD) 30.1 ± 9.6 28.7 ± 12.0
sBR-BDCAF, median/minimum–maximum 0/0 – 0 3/2 – 4
Medications 26 (83.9) 29 (93.5) 28 (93.3) 23 (76.7)
 Colchicine 14 (45.2) 11 (35.5) 15 (50.0) 5 (16.7)
 Azathioprine 14 (45.2) 10 (32.5) 16 (53.3) 4 (13.3)
 Thalidomide 2 (6.5) 7 (22.6) 3 (10.0) 3 (10.0)
 Methotrexate 3 (9.7) 6 (19.4) 1 (3.3) 3 (10.0)
 Cyclophosphamide 0* 7 (22.6) 5 (16.7)c 2 (6.7)
 Penicillin G benzathine 4 (12.9) 7 (22.6) 4 (13.3) 4 (13.3)
 Anti-TNF 5 (16.1) 0 1 (3.3) 1 (3.3)
 Corticosteroids     
  High dose 5 (16.1)d 13 (41.9) 15 (50.0)d 12 (40.0)
  Low dose 5 (16.1) 18 (58.1) 6 (20.0) 10 (33.3)
 Cyclosporine 1 (3.2) 6 (19.4) 6 (20.0) 5 (16.7)
 Pentoxifylline 2 (6.5) 2 (6.5) 1 (3.3) 2 (6.7)
 Minocycline 0 3 (9.7) 0 0
 Dapsone 0 0 0 1 (3.3)
 Chlorambucil 0 2 (6.5) 0 1 (3.3)
 Sulfasalazine 0 1 (3.2) 0 0
  1. Abbreviations: aBD Active Behçet’s disease, BD Behçet’s disease, CNS Central nervous system, iBD Inactive Behçet’s disease, sBR-BDCAF Simplified Behçet’s Disease Current Activity Form adapted for Portuguese by the Sociedade Brasileira de Reumatologia, TNF Tumor necrosis factor
  2. aIncluded cases with optic neuritis, vitreous hemorrhage, sudden blindness, and so forth
  3. bOther manifestations: BD-induced dementia, arthralgia/arthritis, folliculitis decalvans, and so forth
  4. c p < 0.05
  5. d p < 0.01